Recently, using a cell-free DNA (cfDNA) assay that covered the entire coding region of RET, L730V and T729_L730insL were found as on-target acquired mutations in cfDNA of RET fusion-positive NSCLC patients who developed resistance to pralsetinib15. This evidence concerns the gene RET and non-small cell lung carcinoma.